132 related articles for article (PubMed ID: 9421473)
1. CTS1: a p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties.
Conseiller E; Debussche L; Landais D; Venot C; Maratrat M; Sierra V; Tocque B; Bracco L
J Clin Invest; 1998 Jan; 101(1):120-7. PubMed ID: 9421473
[TBL] [Abstract][Full Text] [Related]
2. Cancer gene therapy mediated by CTS1, a p53 derivative: advantage over wild-type p53 in growth inhibition of human tumors overexpressing MDM2.
Bougeret C; Virone-Oddos A; Adeline E; Lacroix F; Lefranc C; Ferrero L; Huet T
Cancer Gene Ther; 2000 May; 7(5):789-98. PubMed ID: 10830726
[TBL] [Abstract][Full Text] [Related]
3. Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand.
Naumann U; Kügler S; Wolburg H; Wick W; Rascher G; Schulz JB; Conseiller E; Bähr M; Weller M
Cancer Res; 2001 Aug; 61(15):5833-42. PubMed ID: 11479223
[TBL] [Abstract][Full Text] [Related]
4. MDMX: a novel p53-binding protein with some functional properties of MDM2.
Shvarts A; Steegenga WT; Riteco N; van Laar T; Dekker P; Bazuine M; van Ham RC; van der Houven van Oordt W; Hateboer G; van der Eb AJ; Jochemsen AG
EMBO J; 1996 Oct; 15(19):5349-57. PubMed ID: 8895579
[TBL] [Abstract][Full Text] [Related]
5. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.
Honda R; Yasuda H
EMBO J; 1999 Jan; 18(1):22-7. PubMed ID: 9878046
[TBL] [Abstract][Full Text] [Related]
6. Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis.
Heessen S; Leonchiks A; Issaeva N; Sharipo A; Selivanova G; Masucci MG; Dantuma NP
Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1532-7. PubMed ID: 11805282
[TBL] [Abstract][Full Text] [Related]
7. Regulation of human p53 activity and cell localization by alternative splicing.
Ghosh A; Stewart D; Matlashewski G
Mol Cell Biol; 2004 Sep; 24(18):7987-97. PubMed ID: 15340061
[TBL] [Abstract][Full Text] [Related]
8. Oligomerisation of full length p53 contributes to the interaction with mdm2 but not HPV E6.
Marston NJ; Jenkins JR; Vousden KH
Oncogene; 1995 May; 10(9):1709-15. PubMed ID: 7753547
[TBL] [Abstract][Full Text] [Related]
9. Multiple lysine mutations in the C-terminus of p53 make it resistant to degradation mediated by MDM2 but not by human papillomavirus E6 and induce growth inhibition in MDM2-overexpressing cells.
Nakamura S; Roth JA; Mukhopadhyay T
Oncogene; 2002 Apr; 21(16):2605-10. PubMed ID: 11971195
[TBL] [Abstract][Full Text] [Related]
10. Escape of p53 protein from E6-mediated degradation in HeLa cells after cisplatin therapy.
Wesierska-Gadek J; Schloffer D; Kotala V; Horky M
Int J Cancer; 2002 Sep; 101(2):128-36. PubMed ID: 12209989
[TBL] [Abstract][Full Text] [Related]
11. Increased apoptosis induction by 121F mutant p53.
Saller E; Tom E; Brunori M; Otter M; Estreicher A; Mack DH; Iggo R
EMBO J; 1999 Aug; 18(16):4424-37. PubMed ID: 10449408
[TBL] [Abstract][Full Text] [Related]
12. Mdm2 promotes the rapid degradation of p53.
Haupt Y; Maya R; Kazaz A; Oren M
Nature; 1997 May; 387(6630):296-9. PubMed ID: 9153395
[TBL] [Abstract][Full Text] [Related]
13. Gamma interferon-inducible protein 10 induces HeLa cell apoptosis through a p53-dependent pathway initiated by suppression of human papillomavirus type 18 E6 and E7 expression.
Zhang HM; Yuan J; Cheung P; Chau D; Wong BW; McManus BM; Yang D
Mol Cell Biol; 2005 Jul; 25(14):6247-58. PubMed ID: 15988033
[TBL] [Abstract][Full Text] [Related]
14. The domain of p53 required for binding HPV 16 E6 is separable from the degradation domain.
Mansur CP; Marcus B; Dalal S; Androphy EJ
Oncogene; 1995 Feb; 10(3):457-65. PubMed ID: 7845670
[TBL] [Abstract][Full Text] [Related]
15. HPV-18 E6 mediated inhibition of p53 DNA binding activity is independent of E6 induced degradation.
Thomas M; Massimi P; Jenkins J; Banks L
Oncogene; 1995 Jan; 10(2):261-8. PubMed ID: 7838526
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of the p53-mdm2 and p53-MDMX interfaces.
Böttger V; Böttger A; Garcia-Echeverria C; Ramos YF; van der Eb AJ; Jochemsen AG; Lane DP
Oncogene; 1999 Jan; 18(1):189-99. PubMed ID: 9926934
[TBL] [Abstract][Full Text] [Related]
17. Mdm2: keeping p53 under control.
Piette J; Neel H; Maréchal V
Oncogene; 1997 Aug; 15(9):1001-10. PubMed ID: 9285554
[TBL] [Abstract][Full Text] [Related]
18. Papillomavirus E2 induces p53-independent apoptosis in HeLa cells.
Desaintes C; Goyat S; Garbay S; Yaniv M; Thierry F
Oncogene; 1999 Aug; 18(32):4538-45. PubMed ID: 10467398
[TBL] [Abstract][Full Text] [Related]
19. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.
Landers JE; Cassel SL; George DL
Cancer Res; 1997 Aug; 57(16):3562-8. PubMed ID: 9270029
[TBL] [Abstract][Full Text] [Related]
20. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo.
Böttger A; Böttger V; Sparks A; Liu WL; Howard SF; Lane DP
Curr Biol; 1997 Nov; 7(11):860-9. PubMed ID: 9382809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
